$ICUI (ICU Medical, Inc.)

$ICUI {{ '2016-10-06T13:09:49+0000' | timeago}} • Announcement

$ICUI expects to report 3Q16 revenue of about $96MM, adjusted EBITDA of about $33.5MM and adjusted EPS of $1.20. For 2016, the company expects to report results slightly above the high-end of previously announced revenue outlook of $370MM, adjusted EBITDA estimate of $131MM and adjusted EPS guidance of $4.60.

$UNH {{ '2018-01-17T18:35:18+0000' | timeago}} • Webcast

For 2018, health insurance provider UnitedHealth expects its profits between $16.7-17.3Bil. $UNH expects its premium revenues to reduce $400-500MM due to regulatory changes in Affordable Care Act. The company also plans to invest $200-300MM this year in artificial intelligence, data analytics etc. which would improve its engagement with customers.

$UNH {{ '2018-01-17T18:34:42+0000' | timeago}} • Webcast

UnitedHealth's 2017 medical care ratio increased 90 basis points to 82.1% vs. last year. Medical care ratio shows how much money is spent on healthcare from the premiums received by the health insurer. $UNH expects its 2018 medical care ratio to come around 81.5% plus or minus 50 basis points.

$UNH {{ '2018-01-17T18:34:08+0000' | timeago}} • Webcast

UnitedHealth's 4Q profits spiked to $3.62Bil whereas revenue was up 9% to $52.06Bil. $UNH's Health Insurance segment brings in more revenues, but Optum segment contributed more to its profits. Optum's profits were up 22% reaching $2.2Bil in 4Q. For 2017, the company reported a non-cash tax benefit of $1.22 per share due to tax reforms.

$UNH {{ '2018-01-17T13:48:18+0000' | timeago}} • Announcement

Largest US health insurer UnitedHealth's profits more than doubled in the fourth quarter to $3.61Bil due to tax benefits. $UNH also crossed $200Bil mark in revenues for FY17. The company now expects to save $1.7Bil in FY18 due to tax reforms. For 2018, the health insurer expects GAAP EPS between $11.65-11.95 and non-GAAP EPS between $12.30-12.60.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$UNH {{ '2018-01-16T17:58:43+0000' | timeago}} • Infographic

$UNH UnitedHealth Group Incorporated Earnings AlphaGraphic: Q4 2017 Highlights

$MDT {{ '2018-01-16T17:16:57+0000' | timeago}} • Announcement

$MDT received FDA clearance of the Riptide Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio. This is designed to retrieve thrombus (or blood clot) through the Arc Catheter and restore blood flow in patients experiencing blockage of an artery in the brain, known as an ischemic stroke.

$MDXG {{ '2018-01-16T15:33:54+0000' | timeago}} • Announcement

$MDXG announced the first patients have been randomized and enrolled in the pivotal Phase 3 Investigational New Drug clinical trial to assess the safety and efficacy of AmnioFix Injectable in patients with recalcitrant plantar fasciitis pain, which is most common in chronic heel pain in adults. Top-line results from this study are expected in 2H19.

$MDXG {{ '2018-01-11T20:52:15+0000' | timeago}} • Announcement

$MDXG successfully settled its longstanding patent infringement lawsuit against Musculoskeletal Transplant Foundation, Inc., Medline Industries, Inc. and Liventa Bioscience, Inc. The company has obtained a Consent Decree and Final Judgment on the validity of the patent and will receive an undisclosed monetary sum.

$LIVN {{ '2018-01-11T17:37:05+0000' | timeago}} • Announcement

$LIVN said the first patient has been enrolled in the Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-Surgical Aortic Valve Implant Study. The study is expected to enroll about 230 patients at 15 sites from the U.S. and Canada to ascertain whether valve leaflets are fully operational following surgery.

$MDT {{ '2018-01-10T14:44:35+0000' | timeago}} • Announcement

The FDA has approved an innovative clinician programmer for the SynchroMed-II Intrathecal Drug Delivery system developed by medical technology company $MDT, for chronic pain and spasticity. SynchroMed-II, an implantable pump, delivers medication directly to the fluid around the spinal cord. It is an app that facilitates simple, guided workflows.

$SYK {{ '2018-01-09T17:21:37+0000' | timeago}} • Announcement

$SYK said that for 4Q17 its preliminary results are of net sales growth of 10% to $3.5Bil, while for FY17, its net sales grew 9.9% to $12.4Bil. Excluding the impact of foreign currency & acquisitions, net sales rose 8.1% and 7.1% in 4Q17 and FY17. For 2018, $SYK expects modest headwinds that will be manageable within its overall financial targets.

$OFIX {{ '2018-01-09T17:10:48+0000' | timeago}} • Announcement

$OFIX announced preliminary  4Q17 net sales of approx $117MM. These preliminary results represent reported sales growth of 7.7% and constant currency sales growth of 6.1% over 4Q16. As of Dec 31, 2017, cash and cash equivalents were approx $81MM compared to $40MM as of Dec 31, 2016.

$HRC {{ '2018-01-09T17:07:14+0000' | timeago}} • Announcement

$HRC announced its preliminary 1Q18 revenue. For this period, the company expects worldwide revenue of approx $670MM, an increase of 5% YoY. Core revenue increased approx 2%, exceeding the company's previously issued guidance of flat core revenue growth.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$CELG {{ '2018-01-08T19:25:23+0000' | timeago}} • Announcement

$CELG announced preliminary results for 4Q17 and FY17. Celgene also provided the outlook for FY18 and reaffirmed FY20 guidance. The company is expected to finalize these results when it announces the earnings results on Jan. 25, 2018.

$LIVN {{ '2018-01-08T14:58:25+0000' | timeago}} • Announcement

$LIVN announced Matthew J. Dodds has joined the company as SVP, Corporate Development. In this role, Dodds is responsible for Business Development, Investor Relations and Corporate Communications.

$CELG {{ '2018-01-08T14:00:46+0000' | timeago}} • Announcement

$CELG agreed to acquire start-up firm Impact Biomedicines for an upfront payment of $1.1Bil. Under the deal terms, Celgene will further pay up to $1.25Bil on Impact's cancer drug Fedratinib getting FDA's approvals. If the global annual net sales of the drug exceed $5Bil, Celgene will pay a maximum of $4.5Bil. The deal is expected to close in 1Q18.

$MDXG {{ '2018-01-08T13:35:17+0000' | timeago}} • Announcement

$MDXG, a biopharmaceutical company, said it estimates 4Q17 revenues to be $90.9MM, up 30% compared to last year. For fiscal 2017, the company sees revenue of $324.5MM, higher by 32% from last year.

$IART {{ '2018-01-08T12:15:32+0000' | timeago}} • Announcement

$IART said it expects 4Q17 revenue to be approx $365MM, an increase of over 40% compared to 4Q16, helped by Derma Sciences and Codman Neurosurgery acquisitions. The results will be announced in late February, 2018.

Recent Transcripts

UNH (UnitedHealth Group Incorporated)
Tuesday, January 16 2018 - 1:45pm
MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
ICUI (ICU Medical, Inc.)
Thursday, November 9 2017 - 9:30pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
HAE (Haemonetics Corporation)
Tuesday, November 7 2017 - 1:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
LIVN (LivaNova PLC)
Thursday, November 2 2017 - 1:00pm
RTIX (RTI Surgical Inc.)
Thursday, November 2 2017 - 12:30pm
TFX (Teleflex Incorporated)
Thursday, November 2 2017 - 12:00pm
BDX (Becton, Dickinson and Company)
Thursday, November 2 2017 - 12:00pm
WMGI (Wright Medical Group N.V.)
Wednesday, November 1 2017 - 8:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
MASI (Masimo Corporation)
Tuesday, October 31 2017 - 8:30pm
OFIX (Orthofix International N.V.)
Monday, October 30 2017 - 8:30pm
MDXG (MiMedx Group, Inc.)
Friday, October 27 2017 - 2:30pm
RMD (ResMed Inc.)
Thursday, October 26 2017 - 8:30pm

AlphaGraphics you may like